Development of small-molecules targeting CD93-signaling for the treatment of leukemia
Description
The aim of the current InnoSuisse application is to optimize small molecules, which were identified in a drug library screen to block CD93-signaling in LSCs and showed a positive clinical response, in order to develop lead candidates with a novel chemical scaffold and own IP to treat leukemia.
Key Data
Projectlead
Prof. Dr. Rainer Riedl, Dr. Carsten Riether
Project team
Dr. Michael Brand
Project partners
Inselspital Bern
Project status
completed, 01/2021 - 07/2022
Funding partner
Innovationsprojekt / Projekt Nr. 47219.1 IP-LS
Project budget
483'000 CHF
Einsiedlerstrasse 31
8820 Wädenswil